Conjugate Vaccine Market
Global Conjugate Vaccine Market Size, Share & Trends Analysis Report By Product Type (Multivalent Conjugate Vaccines, Monovalent Conjugate Vaccines) By Disease (Meningococcal, Diphtheria Tetanus Pertussis, Influenza, Pneumococcal, and Others) By Patient Type (Adults and Pediatrics) By Pathogen Type (Bacterial Conjugate Vaccine, Viral Conjugate Vaccine and Combination Vaccine) Forecast 2022-2028 Update Available - Forecast 2024-2030
The global conjugate vaccine market is anticipated to grow at a considerable CAGR of 10.2% during the forecast period.. Conjugate vaccines are similar to recombinant vaccines manufactured by the combination of two different components and made by pieces from the coat of bacteria. These coats are chemically linked to a carrier protein, and the combination is used as a vaccine. Conjugate vaccines are used to create a more powerful, combined immune response from infectious diseases. The increasing demand of vaccine for treating meningococcal, influenza, pneumococcal, and other disease is contributing to the growth of the market. Pathogens including bacteria, fungi or viruses, are the main carrier of the disease with the highest global burden seen with bacterial meningitis According to WHO, around 1 in 10 people who get bacterial meningitis die and 1 in 5 have severe complications. In addition, factors such as rising incidence and prevalence of chronic diseases globally, is increasing adoption of conjugate vaccine which is expected to fuel the growth of global conjugate vaccine market. According to The Confederation of Meningitis Organizations (CoMO), Bacterial meningitis is the most severe and common form of meningitis, and which cause around 170,000 deaths globally every year.
Impact of COVID-19 Pandemic on Global Conjugate Vaccine Market
The COVID-19 pandemic affected almost every country across the globe. Due to COVID-19 pandemic, limited transportation options and travel restrictions created hurdles to international trade and transportation, which disrupted the supply chain for the conjugate vaccine market, resulting declination in the demand for the vaccine. The interruption in immunization campaigns and a decrease in vaccination rate has created enormous load on the healthcare systems. The COVID-19 pandemic applied pressure on global manufacturer production capacities, supply availability and logistics. According to UNICEF, in 2019, it procured around 2.43 billion doses of vaccines to around 100 countries to reach approximately 45% of the world’s children under five.
Segmental Outlook
The global conjugate vaccine market is segmented based on product type, disease, patient type and pathogen type. Based on product type the market is segmented into multivalent conjugate vaccines, and monovalent conjugate vaccines. Based on disease the market is bifurcated into meningococcal, diphtheria tetanus pertussis, influenza, pneumococcal, and others. Based on patient type the market is segmented into adults and children. Based on pathogen type the market is segmented into bacterial conjugate vaccine, viral conjugate vaccine and combination vaccine. Based on product, the monovalent conjugate vaccine is anticipated to grow at the higher rate. monovalent conjugate.
Global Conjugate vaccine Market Share by Patient Type, 2021 (%)
The Pediatric Segment is Predicated to Account for the Largest Revenue share in the Global Conjugate Vaccine Market
Based on patient, the children segment is accounted to hold the prominent market share during the forecast period. Innovations and development in immunological technologies and different vaccines along with an upsurge in the prevalence rate of the different types of infectious diseases among children has propelled the pediatric segment of the global conjugate vaccine market. The different type Pneumococcal disease common among children are pneumonia, sinusitis, meningitis, osteomyelitis, bacteraemia, and septic arthritis, and ear infections. According to UNICEF, pneumonia is the leading infectious diseases, killing around 800,000 children a year. Due to increasing its prevalence, the demand for conjugate vaccine can be expected to increase during the forecast.
Regional Outlooks
The global conjugate vaccine market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). North America dominated the market in 2021, and it is further projected to maintain its dominance throughout the forecasted period. The regional growth is attributed to rise in demand for pneumococcal, meningococcal,and other conjugate vaccines, presence of awell-established healthcare infrastructure, and significant healthcare investment in major economies such as the US and Canada.
Global Conjugate vaccine Market Growth, by Region 2021-2028
The Asia-Pacific Region is Emerged as Fastest Growing in Global Conjugate vaccine Market
The Asia-Pacific region is estimated to account for the significant share and to show fastest growth in the global conjugate vaccine market. The improvement and advancements in medical science coupled with infectious diseases in the region is contributing to the growth of the market. Also, the awareness about various infectious diseases is boosting the global conjugated vaccine market. According to WHO, diarrhoea is one of the leading killer of young children. According to the WHO report in 2017, diarrhoea killed approximately 480,000 young children globally. The demand for vaccines for the disease is contributing for the growth of the market. Moreover, the development and production of new vaccines, expansion of the median age population, are further boosting the growth of the market.
Market Players Outlook
The major companies serving the global conjugate vaccine market are Serum Institute of India Pvt. Ltd., Sanofi Pasteur, Pfizer, Novartis AG and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, geographical expansion, and new product launches, to stay competitive in the market. For instance, in 2020, Sanofi Pasteur got MenQuadfi approved by the USFDA , which is the latest innovation in meningococcal (MenACWY) vaccination. Which will help protect an expanded age group and elicits a high immune response across multiple ages.
The Report Covers
- Market value data analysis of 2022 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global conjugate vaccine market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Conjugate vaccine Market
• Recovery Scenario of Global Conjugate vaccine Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Ananlysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Conjugate Vaccine Market, by Product Type
4.1.1. Multivalent Conjugate Vaccine
4.1.2. Monovalent Conjugate Vaccine
4.2. Global Conjugate Vaccine Market, by Disease
4.2.1. Meningococcal
4.2.2. Diphtheria Tetanus Pertussis
4.2.3. Influenza
4.2.4. Pneumococcal
4.2.5. Others
4.3. Global Conjugate Vaccine Market, by Patient type
4.3.1. Adults
4.3.2. Pediatric
4.4. Global Conjugate Vaccine Market, by Pathogen type
4.4.1. Bacterial Conjugate Vaccine
4.4.2. Viral Conjugate Vaccine
4.4.3. Combination Vaccine
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Astellas Pharma Inc.
6.2. Astrazeneca
6.3. Bharat Biotech
6.4. Biological E Ltd.
6.5. Bavarian Nordic
6.6. CSL Behring
6.7. Daiichi Sankyo Company, Ltd.
6.8. Emergent BioSolutions, Inc
6.9. Glaxosmithkline Plc.
6.10. Johnson & Johnson
6.11. Merck & Co.
6.12. Mitsubishi Tanabe Pharma Corp
6.13. Medimmune, LLC
6.14. Neuron Biotech
6.15. Novartis AG
6.16. Sanofi Pasteur
6.17. SutroVax Inc.
6.18. Pfizer, Inc.
6.19. Serum Institute Of India Pvt. Ltd
1. GLOBAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028($ MILLION)
2. GLOBAL MULTIVALENT CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL MONOVALENT CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
5. GLOBAL CONJUGATE VACCINE FOR MENINGOCOCCAL, MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL CONJUGATE VACCINE FOR DIPHTHERIA TETANUS PERTUSSIS, MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL CONJUGATE VACCINE FOR INFLUENZA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL CONJUGATE VACCINE FOR PNEUMOCOCCAL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL CONJUGATE VACCINE FOR OTHER DISEASE, MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATIENT TYPE, 2021-2028 ($ MILLION)
11. GLOBAL CONJUGATE VACCINE FOR ADULTS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL CONJUGATE VACCINE FOR PEDIATRICSMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATHOGEN TYPE, 2021-2028 ($ MILLION)
14. GLOBAL BACTERIAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15. GLOBAL VIRAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
16. GLOBAL COMBINATION CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
17. GLOBAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
18. NORTH AMERICAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. NORTH AMERICAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
20. NORTH AMERICAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
21. NORTH AMERICAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATIENT TYPE, 2021-2028 ($ MILLION)
22. NORTH AMERICAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATHOGEN TYPE, 2021-2028 ($ MILLION)
23. EUROPEAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
24. EUROPEAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
25. EUROPEAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
26. EUROPEAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATIENT TYPE, 2021-2028 ($ MILLION)
27. EUROPEAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATHOGEN TYPE, 2021-2028 ($ MILLION)
28. ASIA-PACIFIC CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
29. ASIA-PACIFIC CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
30. ASIA-PACIFIC CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
31. ASIA-PACIFIC CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATIENT TYPE, 2021-2028 ($ MILLION)
32. ASIA-PACIFIC CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATHOGEN TYPE , 2021-2028 ($ MILLION)
33. REST OF THE WORLD CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
34. REST OF THE WORLD CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
35. REST OF THE WORLD CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
36. REST OF THE WORLD CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATIENT TYPE, 2021-2028 ($ MILLION)
37. REST OF THE WORLD CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATHOGEN TYPE, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL CONJUGATE VACCINE MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL CONJUGATE VACCINE MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL CONJUGATE VACCINE MARKET, 2021-2028 (%)
4. GLOBAL CONJUGATE VACCINE MARKET SHARE BY PRODUCT TYPE, 2021 VS 2028 (%)
5. GLOBAL MULTIVALENT CONJUGATE VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL MONOVALENT CONJUGATE VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL CONJUGATE VACCINE MARKET SHARE BY DISEASE, 2021 VS 2028 (%)
8. GLOBAL CONJUGATE VACCINE FOR MENINGOCOCCAL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL CONJUGATE VACCINE MARKET FOR DIPHTHERIA TETANUS PERTUSSIS SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL CONJUGATE VACCINE FOR INFLUENZA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL CONJUGATE VACCINE FOR PNEUMOCOCCAL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL CONJUGATE VACCINE FOR OTHER DISEASE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL CONJUGATE VACCINE MARKET SHARE BY PATIENT TYPE, 2021 VS 2028 (%)
14. GLOBAL CONJUGATE VACCINE FOR ADULTS MARKET SHARE BY GEOGRAPHY 2021 VS 2028 (%)
15. GLOBAL CONJUGATE VACCINE FOR PEDIATRICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. GLOBAL CONJUGATE VACCINE MARKET SHARE BY PATHOGEN TYPE, 2021 VS 2028 (%)
17. GLOBAL BACTERIAL CONJUGATE VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
18. GLOBAL VIRAL CONJUGATE VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
19. GLOBAL COMBINATION CONJUGATE VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
20. US CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
21. CANADA CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
22. UK CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
23. FRANCE CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
24. GERMANY CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
25. ITALY CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
26. SPAIN CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF EUROPE CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
28. INDIA CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
29. CHINA CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
30. JAPAN CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
31. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
32. REST OF ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
33. REST OF THE WORLD CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
